Definitive radiotherapy/chemoradiotherapy outcomes and toxicity profile in geriatric patients with cervical cancer: Turkish Society for Radiation Oncology Geriatric Oncology Group study (TROD 013-002)

Background: To investigate the treatment outcomes, prognostic factors for survival and toxicities in patients older than 65 years with cervical cancer who underwent definitive radiotherapy/chemoradiotherapy and compare the treatment outcomes between the older elderly (≥75 years) and younger elderly (65–74 years) patients. Methods: The clinical records of 458 patients with cervical cancer were retrospectively reviewed. There were 365 (79.7%) patients who received concurrent chemoradiotherapy and 93 (20.3%) patients who received radiotherapy alone. Radiotherapy was in the form of external beam radiotherapy followed by brachytherapy. Clinicopathological factors and treatment strategies were compared between the two age groups. Results: The median age was 71 years (range: 65–91 years). 71% of patients were in the younger elderly group while 29% were in the older elderly group. Concomitant chemotherapy and brachytherapy were more commonly applied to these patients. Median follow-up was 48 months. The overall survival rate was significantly lower in patients in the older elderly group. The 5-year survival rate was 67.3% in the younger age group compared to 46.1% in the older elderly group. Patients demonstrated statistically significantly higher overall survival rates with chemoradiotherapy compared to radiotherapy alone in both age groups. In multivariate analysis, treatment response and lymph node involvement were found to be significant independent prognostic factors for overall survival, cancer-specific survival, distant metastasis-free survival and disease-free survival. Performance status was found to be an additional factor for overall survival and disease-free survival. The type of treatment, whether chemoradiotherapy or radiotherapy alone and age were also found to be significant independent prognostic factors for overall survival. Conclusions: A curative treatment approach in the geriatric group with locally advanced cervical cancer results in high survival rates with a low toxicity profile. In patients whose health status permits, definitive chemoradiotherapy followed by brachytherapy is considered appropriate.

Geriatric patients; Older cervical cancer; Chemoradiotherapy; Survival; Prognostic factor; Toxicity

[1] Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. International Journal of Cancer. 2021; 149: 778–789.

[2] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021; 71: 209–249.

[3] Beavis AL, Gravitt PE, Rositch AF. Hysterectomy-corrected cervical cancer mortality rates reveal a larger racial disparity in the United States. Cancer. 2017; 123: 1044–1050.

[4] Rositch AF, Nowak RG, Gravitt PE. Increased age and race-specific incidence of cervical cancer after correction for hysterectomy prevalence in the United States from 2000 to 2009. Cancer. 2014; 120: 2032–2038.

[5] Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. Journal of Clinical Oncology. 2011; 29: 3457–3465.

[6] Elit L. Cervical cancer in the older woman. Maturitas. 2014; 78: 160–167.

[7] Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2017; 28: iv72–iv83.

[8] Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. The Cochrane Database of Systematic Reviews. 2010; 2010: CD008285.

[9] Park JH, Kim YS, Ahn SD, Choi EK, Shin SS, Kim YT, et al. Concurrent chemoradiotherapy or radiotherapy alone for locally advanced cervical cancer in elderly women. Tumori. 2010; 96: 959–965.

[10] Wang W, Hou X, Yan J, Shen J, Lian X, Sun S, et al. Outcome and toxicity of radical radiotherapy or concurrent chemoradiotherapy for elderly cervical cancer women. BMC Cancer. 2017; 17: 510.

[11] Vitale SG, Capriglione S, Zito G, Lopez S, Gulino FA, Di Guardo F, et al. Management of endometrial, ovarian and cervical cancer in the elderly: current approach to a challenging condition. Archives of Gynecology and Obstetrics. 2019; 299: 299–315.

[12] Shimamoto K, Saito T, Kitade S, Tomita Y, Nagayama R, Yamaguchi S, et al. A study of treatments and outcomes in elderly women with cervical cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2018; 228: 174–179.

[13] Bhatla N, Berek JS, Cuello Fredes M, Denny LA, Grenman S, Karunaratne K, et al. Revised FIGO staging for carcinoma of the cervix uteri. International Journal of Gynaecology and Obstetrics. 2019; 145: 129–135.

[14] Lim K, Small W, Portelance L, Creutzberg C, Jürgenliemk-Schulz IM, Mundt A, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. International Journal of Radiation Oncology, Biology, Physics. 2011; 79: 348–355.

[15] Haie-Meder C, Pötter R, Van Limbergen E, Briot E, De Brabandere M, Dimopoulos J, et al. Recommendations from gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image-based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiotherapy & Oncology. 2005; 74: 235–245.

[16] Mitsuhashi N, Takahashi M, Nozaki M, Yamakawa M, Takahashi T, Sakurai H, et al. Squamous cell carcinoma of the uterine cervix: radiation therapy for patients aged 70 years and older. Radiology. 1995; 194: 141–145.

[17] Mitchell PA, Waggoner S, Rotmensch J, Mundt AJ. Cervical cancer in the elderly treated with radiation therapy. Gynecologic Oncology. 1998; 71: 291–298.

[18] Lindegaard JC, Thranov IR, Engelholm SA. Radiotherapy in the management of cervical cancer in elderly patients. Radiotherapy & Oncology. 2000; 56: 9–15.

[19] Sakurai H, Mitsuhashi N, Takahashi M, Yamakawa M, Akimoto T, Hayakawa K, et al. Radiation therapy for elderly patients with squamous cell carcinoma of the uterine cervix. Gynecologic Oncology. 2000; 77: 116–120.

[20] Chen SW, Liang JA, Yang SN, Lin FJ. High dose-rate brachytherapy for elderly patients with uterine cervical cancer. Japanese Journal of Clinical Oncology. 2003; 33: 221–228.

[21] Ikushima H, Takegawa Y, Osaki K, Furutani S, Yamashita K, Kawanaka T, et al. Radiation therapy for cervical cancer in the elderly. Gynecologic Oncology. 2007; 107: 339–343.

[22] Nosaka K, Shibata K, Utsumi F, Yoshida K, Niimi K, Sekiya R, et al. Feasibility and benefit of concurrent chemoradiotherapy for elderly patients with uterine cervical cancer. Tumori. 2016; 102: 600–605.

[23] Guler OC, Sari SY, Birgi SD, Gultekin M, Yildiz F, Onal C. Definitive chemoradiotherapy in elderly cervical cancer patients: a multiinstitutional analysis. International Journal of Gynecological Cancer. 2017; 27: 1446–1454.

[24] Hata M, Koike I, Miyagi E, Numazaki R, Asai-Sato M, Kasuya T, et al. Radiation therapy for very elderly patients aged 80 years and older with squamous cell carcinoma of the uterine cervix. American Journal of Clinical Oncology. 2017; 40: 178–182.

[25] You KY, Peng HH, Jiang YH, Bi ZF, Qiu XS. Selective use of concurrent chemotherapy in elderly cervical cancer patients treated with definitive radiotherapy: experience from two institutions. Cancer Management and Research. 2019; 11: 4815–4823.

[26] Sarma G, Borah L, Nath J, Bhattacharyya M, Medhi PP, Kalita AK. Treatment outcomes and patterns of failure in elderly patients with cervical cancer treated with definitive radiotherapy. Turkish Journal of Oncology. 2021; 36: 61–70.

[27] Nogueira-Rodrigues A, de Melo AC, Garces AH, Paulino E, Alves FV, Vilaça Mdo N, et al. Patterns of care and outcome of elderly women diagnosed with cervical cancer in the developing world. International Journal of Gynecological Cancer. 2016; 26: 1246–1251.

[28] Wright JD, Gibb RK, Geevarghese S, Powell MA, Herzog TJ, Mutch DG, et al. Cervical carcinoma in the elderly: an analysis of patterns of care and outcome. Cancer. 2005; 103: 85–91.

[29] Albert A, Lee A, Allbright R, Vijayakumar S. Impact of age on receipt of curative treatment for cervical cancer: an analysis of patterns of care and survival in a large, national cohort. Journal of Geriatric Oncology. 2019; 10: 465–474.

[30] Goodheart M, Jacobson G, Smith BJ, Zhou L. Chemoradiation for invasive cervical cancer in elderly patients: outcomes and morbidity. International Journal of Gynecological Cancer. 2008; 18: 95–103.

[31] Leetanaporn K, Hanprasertpong J. Addition of chemotherapy to radiation is associated with improved survival in older patients with cervical cancer: a surveillance, epidemiology, and end results database analysis. International Journal of Gynecological Cancer. 2025; 35: 101633.

[32] Liao JF, Xu T, Zhou JM, Xiao NJ, Zhao M, Zhao TS, et al. The impact of chemotherapy on survival in patients aged ≥65 years with locoregionally cervical cancer who undergo radiotherapy: a surveillance, epidemiology, and end results database analysis. International Journal of Gynecological Cancer. 2025; 35: 101747.

[33] Han K, Colson-Fearon D, Liu ZA, Viswanathan AN. Updated trends in the utilization of brachytherapy in cervical cancer in the united states: a surveillance, epidemiology and end-results study. International Journal of Radiation Oncology, Biology, Physics. 2024; 119: 143–153.

[34] Moore KN, Java JJ, Slaughter KN, Rose PG, Lanciano R, DiSilvestro PA, et al. Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis. Gynecologic Oncology. 2016; 143: 294–301.

[35] Quinn BA, Deng X, Colton A, Bandyopadhyay D, Carter JS, Fields EC. Increasing age predicts poor cervical cancer prognosis with subsequent effect on treatment and overall survival. Brachytherapy. 2019; 18: 29–37.

[36] Hanawa S, Mitsuhashi A, Usui H, Yamamoto N, Watanabe-Nemoto M, Nishikimi K, et al. Daily low-dose Cisplatin-based concurrent chemoradiotherapy for the treatment of cervical cancer in patients 70 years or older. International Journal of Gynecological Cancer. 2015; 25: 891–896.

[37] Wang W, Liu X, Meng Q, Zhang F, Hu K. Comparisons of survivals and toxicities between young and elderly patients with cervical cancer treated with definitive radiotherapy or concurrent chemoradiotherapy. Taiwanese Journal of Obstetrics Gynecology. 2019; 58: 364–369.

[38] Chakraborty S, Geetha M, Dessai S, Patil VM. How well do elderly patients with cervical cancer tolerate definitive radiochemotherapy using RapidArc? Results from an institutional audit comparing elderly versus younger patients. Ecancermedicalscience. 2014; 8: 484.